Today's Daily Dose brings you news about Seattle Genetics' pivotal breast cancer trial results; early FDA approval of Vertex Pharma's cystic fibrosis drug; Clearside Biomedical confirming the rejection of XIPERE; double whammy of Aradigm; HealthStream's third-quarter financial results; an update on Odonate Therapeutics' phase III breast cancer trial.
from RTT - Biotech https://ift.tt/2N6I8lw
via IFTTT
No comments:
Post a Comment